Pfizer is in advanced talks to buy Global Blood Therapies the maker of a recently approved drug for sickle cell disease, for about $5 billion, in the drug giant’s latest step to bolster its portfolio and pipeline.
Pfizer is aiming to close a deal for GBT in the coming days, according to people familiar with the matter. The situation is still fluid and other suitors are still in the mix, some people said. GBT will announce its second quarter results on Monday.
.
